Getting a GLP-1 Covered Through a Non-Weight Diagnosis in 2026

Yes, a different diagnosis can change whether a GLP-1 is covered, but only when the drug's FDA label includes that condition and your records document that you have it. As of October 2026, those non-weight indications are heart disease risk reduction and MASH for Wegovy, moderate-to-severe obstructive sleep apnea for Zepbound, and chronic kidney disease in type 2 diabetes for Ozempic. Medicare Part D and Medicaid treat these as covered uses even where weight loss is excluded; commercial plans depend on how their exclusion is written.

Label wording and plan criteria below are as published on the cited FDA-label, CMS, Medicaid and insurer pages as of October 19, 2026. Confirm your own plan's rules in writing.

Why the diagnosis changes the answer

Most coverage denials for GLP-1s are not about the drug. They are about the use. Medicare law bars Part D from covering drugs used specifically for weight loss, but Part D plans can cover GLP-1s for other medically accepted uses, such as type 2 diabetes, cardiovascular risk reduction or sleep apnea (KFF). Many employer plans also carve out "weight loss drugs" as a benefit. A drug approved for a medical condition other than weight is a different use, and payers can treat it differently.

Medicare.gov makes the same split in plain terms. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Medicare GLP-1 Bridge, it says, "but your Part D plan might cover your GLP-1s" (Medicare.gov). Expect a plan covering one of those uses to require prior authorization to confirm the diagnosis.

The FDA-labeled non-weight indications

Sources: Wegovy prescribing information (rev. 6/2026); Zepbound prescribing information (rev. 8/2026); Ozempic prescribing information (rev. 5/2026).

Three details trip people up. The Wegovy pill carries the heart indication but not MASH. Zepbound's sleep apnea indication requires obesity, not just overweight. And Ozempic's kidney indication applies only to people who also have type 2 diabetes, so it is not a path to Ozempic for someone without diabetes.

Medicare Part D

For Medicare, the indication is the whole question. A Part D plan can cover Wegovy for an enrollee with established heart disease and obesity or overweight, or Zepbound for an enrollee with obesity and moderate-to-severe sleep apnea, because those uses are medically accepted. Expect prior authorization that asks for the diagnosis. What you pay then follows your plan's tier, and Part D out-of-pocket spending is limited to $2,100 in 2026 and $2,400 in 2027, according to Medicare.gov.

Separately, CMS runs the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027. It operates outside the regular Part D benefit with a $50 copay that does not count toward the out-of-pocket limit. Medicare.gov lists its eligibility as age 18 or older with a BMI of 35 or higher; a BMI of 30 or higher with diastolic heart failure, uncontrolled high blood pressure or stage 3a or higher kidney disease; or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. People who have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, or who already get a GLP-1 covered through Part D, are not eligible for the Bridge, so for those conditions the regular Part D route is the one that applies.

Medicaid

Medicaid coverage for weight loss is optional for states, but coverage for these other uses is not. KFF notes that Medicaid must cover GLP-1s approved for diabetes, Wegovy for cardiovascular risk reduction, and Zepbound for moderate-to-severe sleep apnea in adults with obesity, though states can add prior authorization and other controls.

That is why states that cut weight-loss coverage in 2026 kept these uses. New Hampshire's January 1, 2026 change continued coverage for type 2 diabetes, cardiovascular events, severe sleep apnea and MASH. MassHealth's July 3, 2026 exclusion kept coverage for BMI over 27 with established heart disease, BMI over 30 with moderate-to-severe sleep apnea, and MASH, but required existing approvals to be resubmitted.

Commercial and employer plans

Private plans vary most. The key is how your plan words its exclusion. Some exclude "drugs used for weight loss," which leaves room to cover the same drug for sleep apnea or heart disease. Others exclude the products themselves, which blocks every use. Cigna's Zepbound coverage policy (effective September 1, 2026) says the member's benefit plan document "always supersedes" the policy, and that plan documents can contain specific exclusions. Ask HR or the plan for the exact exclusion language, not a summary.

What prior authorization usually asks for

Published criteria show what reviewers want. Each example below is from a specific payer, and your plan's rules may differ.

Sleep apnea (Zepbound)

Cigna's policy requires age 18 or older, a baseline BMI of 30 or more, and a sleep study showing an apnea-hypopnea index (AHI) or respiratory event index of 15 or more events per hour, with no central sleep apnea. Approval lasts a year. Renewal requires at least 10% weight loss from baseline and prescriber-reported stabilization of symptoms. It does not require a CPAP trial. Maryland Medicaid's PA form asks for the polysomnography date and AHI, a BMI of 30 or more recorded in the last 90 days, a sleep specialist or pulmonologist involved, and annual repeat documentation after 12 months.

Heart disease (Wegovy)

Maryland's form requires documented established cardiovascular disease, such as a prior heart attack, prior stroke or peripheral arterial disease, with the event date, plus a BMI of 27 or more in the last 90 days. Delaware Medicaid's GLP-1 PA form (revised April 2026) uses the same BMI 27 threshold with established cardiovascular disease.

MASH (Wegovy injection)

Delaware's MASH pathway requires a hepatologist or gastroenterologist and stage F2 to F3 fibrosis confirmed by biopsy or noninvasive testing, with no BMI minimum. Medi-Cal dropped prior authorization for Wegovy for MASH on April 1, 2026 when the claim carries ICD-10 code K75.8 or K76.0, while stating that "Wegovy is not covered for weight loss."

What is not allowed

The diagnosis has to be real and documented in your chart. Asking a prescriber to code sleep apnea without a sleep study, list heart disease you don't have, or record type 2 diabetes to get Ozempic covered for weight loss is misrepresentation to an insurer. It can lead to denied or reversed claims and expose both patient and prescriber to fraud allegations. Diagnosis codes on pharmacy claims, like Medi-Cal's for MASH, make mismatches easy to catch.

The legitimate version is simpler: if you have symptoms such as loud snoring, daytime sleepiness, chest pain history or abnormal liver tests, get them evaluated. If a real diagnosis results, coverage may follow.

What to do

1. Get your plan's exact exclusion language and the drug's prior authorization criteria in writing.
2. Check whether you already have documentation that matches a labeled indication (sleep study, cardiac history, liver staging).
3. If something is missing, ask your doctor whether testing is clinically appropriate.
4. Have your prescriber submit the PA under the labeled indication, with the records attached.
5. If denied, request the denial reason in writing and ask about the appeal process.

Questions to ask your plan

• Does the weight-loss exclusion apply to the drug or only to weight-loss use?
• What documentation does the PA require for sleep apnea, heart disease or MASH?
• Which drug is preferred for this indication?
• How long is approval, and what does renewal require?

Sources

1. Wegovy (semaglutide) prescribing information (rev. 6/2026)
2. Zepbound (tirzepatide) prescribing information (rev. 8/2026)
3. Ozempic (semaglutide) injection prescribing information (rev. 5/2026)
4. Medicare.gov: Costs for Medicare drug coverage
5. CMS: Medicare GLP-1 Bridge
6. KFF: Medicaid coverage of and spending on GLP-1s (Jan. 16, 2026)
7. New Hampshire Medicaid: GLP-1 coverage change notice (Oct. 9, 2025)
8. MassHealth Pharmacy Facts 276 (May 13, 2026, corrected)
9. Cigna: Zepbound coverage policy IP 0816 (effective Sept. 1, 2026)
10. Maryland Medicaid: Wegovy or Zepbound PA form
11. Delaware Medicaid: GLP-1 agonist PA form (rev. April 2026)
12. Medi-Cal Rx: Changes to GLP-1 drug coverage, Wegovy (April 2026)
13. KFF: What to Know About the BALANCE Model and the Medicare GLP-1 Bridge (May 11, 2026)
14. Medicare.gov: Weight loss drugs and the Medicare GLP-1 Bridge

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.